The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. Receive News & Ratings for Amphastar ...

PNC Financial Services Group Inc. lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report ...

Glucagon sales declined to $25.6 million from ... cost of sales associated with them and these sales will be recorded by Amphastar this year, so they will have cost of sales, thus lowering our ...

Amphastar Pharmaceuticals (AMPH ... versus $3.72 million estimated by two analysts on average. Net revenues- Glucagon: $25.62 million versus the two-analyst average estimate of $25.99 million.

JP Morgan says the company has seen some setbacks over the past several months, including a competitive approval for glucagon (~15% of Amphastar revenues) and several pipeline delays. Analyst ...

Gross profit margin dropped to 46.5% from 54.0% a year earlier. Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.

Piper Sandler analyst David Amsellem lowered the firm’s price target on Amphastar (AMPH) to $32 from $36 and keeps a Neutral rating on the shares. Though the firm could envision becoming more ...

Amphastar’s products Baximy and Primatene Mist achieved $102 million in sales. Increased competition is affecting epinephrine vial and glucagon markets. The company anticipates high single-digit ...

Amphastar’s products Baximy and Primatene Mist achieved $102 million in sales. Increased competition is affecting epinephrine vial and glucagon markets. The company anticipates high single-digit ...